SCHEMBL730846

SCHEMBL730846

CC(C)Oc1c[c]cc(-c2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
PTPN5 P54829 1/20 0.40
FFAR4 Q5NUL3 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL732632 0.79 CYP1A1 (0.45) MAPTMEN1KMT2ASMN1; SMN2TP53
SCHEMBL2153929 0.78 ALDH1A1 (0.38) RXRARXRBFFAR4MEN1KMT2A
SCHEMBL8469211 0.77 RXRA (0.72) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL733145 0.76 RXRA (0.47) RXRARXRBMAPTKMT2ASMN1; SMN2
SCHEMBL4178299 0.74 GAA (0.62) RXRARXRBPTPN5MAPTMEN1
SCHEMBL619546 0.73 ALDH1A1 (0.53) MEN1KMT2ACYP3A4CYP1A2ALDH1A1
SCHEMBL12896100 0.71 GABRA1 (0.54) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL21944820 0.71 RXRA (0.51) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL534096 0.71 RXRA (0.59) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL21382696 0.71 ALDH1A1 (0.50) MAPTMEN1KMT2ALMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 RXRA 647/4885RXRB 702/4885GABRA1 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.